A brief review concerning Chimeric Antigen Receptors T cell therapy
| Autor: | Ling-Lin Li, Ren-Chao Zou, Yu-Qiong Yang, Lin Wang, Yuan Hongling |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
medicine.drug_class T cell Cancer Review Biology Monoclonal antibody medicine.disease Chimeric antigen receptor Cell therapy 03 medical and health sciences 030104 developmental biology 0302 clinical medicine Immune system medicine.anatomical_structure Oncology Antigen 030220 oncology & carcinogenesis Chimeric antigen receptors medicine Cancer research Relapse Signal transduction Complication |
| Zdroj: | Journal of Cancer |
| ISSN: | 1837-9664 |
| DOI: | 10.7150/jca.46308 |
| Popis: | The understanding concerning the function of immune system in cancer has achieved considerable advance with time passes by. Manipulating genetically engineered immune cells were investigated as a novel strategy for treating cancer. Chimeric antigen receptors (CARs) are recombinant protein molecules by merging the exquisite targeting the potent cytotoxicity of T cells and specificity of monoclonal antibodies and, which could trigger serial cascades of signal transduction and thereby activate T cells to directly destroy the tumor cells. Manufacturing CAR-modified T lymphocytes were successfully implemented in treating cancer derived from they could specifically retarget tumor-associated antigens, causing effective elimination of tumor cells, which spurred the optimization and development of new CAR-T cell technology. The advancement of synthetic biology methodologies of cell therapy in CAR-T would ultimately provide us with a much safer, reliable and efficient modality to against cancer. This review primarily described the emergence, development and application of cell therapy in CAR-T, then discuss the side effects and the potential factors of tumor reccurrence caused by CAR-T cell therapy, in addition to the corresponding countermeasure concerning complications. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|